Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals (XENE) is a clinical-stage biopharmaceutical company pioneering neuroscience therapies through its innovative extreme genetics platform. This page serves as the definitive source for verified company news, providing investors and researchers with timely updates on therapeutic advancements and strategic developments.
Access curated press releases covering clinical trial milestones, regulatory updates, and research collaborations. Our news collection focuses on XENE's work identifying novel drug targets through genetic analysis of severe disorders, particularly in neurology and psychiatry. Track progress across their pipeline of precision therapies targeting ion channels and neurological pathways.
Key updates include phase trial results, patent filings, executive appointments, and scientific presentations. All content is vetted for accuracy and relevance to investment research. Bookmark this page for efficient monitoring of XENE's progress in genetic-driven drug discovery and partnership announcements within the neuroscience sector.
Xenon Pharmaceuticals (Nasdaq:XENE) presented positive interim data from the Phase 2b open-label extension of its XEN1101 clinical trial for focal onset seizures at the American Epilepsy Society (AES 2022). Key findings show sustained seizure reduction of 80%-90%, with 17.5% and 10.5% of patients achieving 6- and 12-month seizure freedom, respectively. XEN1101 was well-tolerated, and the ongoing Phase 3 program aims to confirm these results. The trial included a difficult-to-treat patient population, suggesting robust efficacy that may enhance XEN1101's market potential.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its participation in one-on-one investor meetings and a fireside chat at the Bank of America Securities Biotech SMID Cap Conference 2022. The event will be held virtually on December 7-8, 2022. Ian Mortimer, President and CEO, along with Sherry Aulin, CFO, will present on December 7 at 1:10 pm Eastern Time. A webcast of the presentation will be accessible on the company’s website for later viewing. Xenon Pharmaceuticals focuses on developing innovative therapies for neurological disorders, particularly epilepsy.
Xenon Pharmaceuticals (Nasdaq:XENE) has announced that President Ian Mortimer and CFO Sherry Aulin will participate in fireside chats and one-on-one meetings at upcoming investor conferences. The events include the Guggenheim 4th Annual Immunology and Neurology Day on November 14, the Stifel 2022 Healthcare Conference on November 15, and the Jefferies London Healthcare Conference on November 17. These presentations aim to engage investors and provide insights into the company’s developments in neurology therapeutics. Additional information can be found on their investors' website.
Xenon Pharmaceuticals has launched its Phase 3 program for XEN1101, initiating the X-TOLE2 clinical trial focused on treating epilepsy. The company maintains a strong financial position with approximately $752 million in cash, ensuring funding for operations through 2026. Despite a significant drop in third-quarter revenue from $8.1 million to $0.1 million due to the end of a collaboration with Neurocrine Biosciences and no milestone payments, R&D expenses have increased to $29.4 million. A conference call to discuss these updates is scheduled for today.
Xenon Pharmaceuticals (NASDAQ:XENE) appointed Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately. DiFabio joins during a critical time as the company advances multiple late-stage clinical programs aimed at commercializing epilepsy therapeutics. With extensive experience in the life sciences sector, she previously held senior legal roles at various biopharmaceutical firms, including Biogen and Repertoire Immune Medicines. Her role will focus on enhancing Xenon’s legal framework and supporting its strategic goals in neurology therapeutics.
Xenon Pharmaceuticals has initiated its Phase 3 program for XEN1101 by launching the X-TOLE2 clinical trial, targeted at treating adult patients with focal epilepsy. This follows positive Phase 2b results and successful discussions with the FDA regarding trial design. The X-TOLE2 and its parallel study, X-TOLE3, aim to evaluate XEN1101's efficacy as an adjunctive treatment, involving approximately 360 patients each. Successful outcomes could lead to a New Drug Application submission. The program reflects Xenon's commitment to addressing unmet medical needs in epilepsy treatment.
Xenon Pharmaceuticals (Nasdaq:XENE) announced it will release its third quarter 2022 financial results on November 8, 2022, after U.S. markets close. The company is focused on developing innovative therapies for neurological disorders, particularly epilepsy. A live conference call and audio webcast will take place at 4:30 PM ET on the same day. Investors can register for participation to receive dial-in details. Xenon is committed to addressing high unmet medical needs in the neurology sector.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will participate in one-on-one investor meetings and a fireside chat at the 17th Annual Wells Fargo Securities Healthcare Conference from September 7-9, 2022. The fireside chat is scheduled for September 8, 2022, from 11:35 am to 12:05 pm ET, featuring President and CEO Ian Mortimer and CCO Chris Von Seggern as presenters. A webcast will be available in the 'Investors' section of Xenon's website, with replays posted afterward. Xenon focuses on developing therapeutics for neurological disorders, particularly epilepsy.
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q2 2022 results, highlighting a cash balance of $788.2 million and a cash runway extended into 2026 following a successful equity offering. The company plans to initiate the XEN1101 Phase 3 program, including the 'X-TOLE2' trial, in the second half of 2022. Recent analyses show XEN1101 rapidly reduced focal onset seizure frequency in prior trials. However, total revenue fell to $0.5 million from $2.2 million year-over-year, contributing to a net loss of $31.2 million, up from $22.1 million in Q2 2021.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will report its Q2 2022 financial and operational results after U.S. markets close on August 9, 2022. The conference call and webcast will be held at 4:30 PM Eastern Time the same day, providing updates on the company’s performance in developing therapeutics for neurological disorders, focusing on epilepsy. Investors can access the live webcast on Xenon's website, with a replay available afterward. The announcement underscores Xenon's commitment to addressing high unmet medical needs in neurology.
FAQ
What is the current stock price of Xenon Pharmaceut (XENE)?
What is the market cap of Xenon Pharmaceut (XENE)?
